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A small expert group met in conclave in July 2010 to define a
long-term strategic research agenda toward further clarification
of the etiology of childhood leukemia (CL). The motivation
and invitation for this project came from the German Office for
Radiation Protection (BfS) because radiation experts have been
puzzled for some time by epidemiological findings of an
increased incidence of CL near German nuclear facilities,1 as
well as by a statistical association with exposure to residential
low-frequency magnetic fields.2 Both findings are difficult to
explain given the current knowledge of the biological mechan-
isms of ionizing or non-ionizing radiation, as both types of
exposure deposit far too little energy in cellular DNA and other
likely targets to be considered directly causative. A previous
workshop on risk factors held in May 20083 and a follow-up
meeting led to the conclusion that understanding of the causes
of CL development requires a broadened, interdisciplinary
approach.
The discussion and work on a research agenda was focused
on the main leukemia type in childhood, acute lympho-
blastic leukemia (ALL), and especially B-cell precursor ALL.
Based on short presentations by all participants and the views of
experts from different disciplines (epidemiology, clinic, experi-
mental modeling, theoretical modeling, molecular biology and
genetics), the following key features and related key questions of
childhood ALL have been developed.
Incidence rates and epidemiological findings
The reported increasing incidence rates seen for B-cell precursor
ALL (but not for T-ALL or acute myelogenous leukemia (AML)) in
industrialized countries4 point toward a role for the modern
lifestyle. However, to date, epidemiological studies have failed
to confirm any associations with lifestyle exposures such
as smoking, alcohol, diet, social status, and so on. Indeed,
to date, the only recognized risk factors for ALL are heavy birth
weight5,6 and gender, with boys more often affected than girls
(approximate ratio 1.2:1).FHowever, the validity of these
annual increases in industrialized countries is questionable.
Are the observed increases partially due to improvements in
cancer registration and disease detection and classification?
What is the base line incidence world wide or, in other words,
how large is the contribution of potentially avoidable environ-
mental factors to the disease? Why are boys more likely
to develop ALL?
So far, epidemiological studies could not correlate various
potential risk factors with the initial versus subsequent genetic
events. A translocation event as the first hit has to be the
consequence of a double-strand break that is misrepaired,
whereas different risk factors reflecting different mechanisms are
supposed to be responsible for the additional cooperating
genetic changes.FWhat does the age at onset of leukemia
tell us? B-cell precursor ALL has a distinct age peak between 2–5
years of age, except for the subtype characterized by mixed
lineage leukemia (MLL) rearrangements that occurs mainly
below 1 year. What are the patterns of incidence of ALL and
AML in developing countriesFis there evidence of a peak
between 2–5 years as seen in developed countries?
Molecular genetics and inherited susceptibilities
Specific chromosomal translocations and DNA aneuploidies are
frequent first hits, but further genetic or epigenetic events must
cooperate to cause an outbreak of acute leukemia. Several
independent genome-wide association studies (GWASs) of a
large number of ALL patients have identified and confirmedReceived 3 November 2010; accepted 19 November 2010
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a handful of gene variants, namely IKZF1, ARIDB5, CEBPE
and CDKN2A,7–12 that affect genomic susceptibility to ALL,
although they are individually modest in their effects. These
gene variants are predominately related to pathways controlling
B-cell development and differentiation. How these germline
variations influence the risk of ALL is unresolved.
Besides the already ongoing GWAS, a strong recommenda-
tion was to initiate next-generation sequencing (whole-genome
or transcriptome sequences, exome capture and sequencing,
analyses of the methylome) of ALL cases, as it is already being
done for other cancer types (see projects of the International
Cancer Genome Consortium). GWASs can reveal population-
based variations, but deep sequencing can focus on detailed
differences and mutations, for example, of tumor versus normal
cells, which could, at least partly, reflect the effects of the
environment. This could help to characterize subgroups that
might not show up in an overall approach, or detect common
patterns/footprints possibly correlated to external risk factors.13
The previous finding that childhood ALL is the consequence of a
limited number of genetic alterations7 supports the feasibility of
identifying the relevant hits.
Studying monozygotic twins, consanguineous siblings
and other familial predisposition syndromes will add valu-
able information on the etiology of ALL, but due to the
limited number of familial cases the latter cannot be studied
systematically.14
The preleukemic clone
Studies of monozygotic twins and retrospective analysis of
neonatal blood spots have found that in many CLs the first hit
that converts a fetal hematopoietic precursor or stem cell to a
preleukemic clone originates in utero.15,16 One study found that
the frequency of newborns carrying the leukemia-specific
translocation TEL-AML1 in their blood is about 100 times
higher than the overall incidence rate of ALL.17 This implies that
preleukemic clones are frequently and normally extinguished
(or at least kept at bay) by natural processes. The preleukemic
‘original’ clones also seem to be of major importance for ALL
relapse.18 Whether the preleukemic clones originated in utero
have also a role in adult leukemia is currently not known.
A recent study published after the meeting19 analyzed 1417
umbilical cord blood samples but did not confirm the findings
by Mori et al., indicating that the frequency of TEL-AML1-
positive cells may be markedly lower in healthy children than
previously suggested. The prevalence of preleukemic clones in
newborns needs to be verified, as it forms the base for many
hypotheses and study designs. Once the frequency of preleu-
kemic clones is established in an industrialized population, it
must be compared with data from developing countries where
less is known about the prevalence of these clones and of ALL
incidence. This would allow us to test whether or not the
observed increasing incidence rates in industrialized countries
are correlated with an increase of initial events or rather of
secondary events.FIn other words: Is the first hit occurring
naturally (at random) or is it already an effect of a factor that can
be prevented? If the first hit occurs naturally, only the secondary
genetic events would be relevant to explain the increasing
incidence rates in developed countries. One critical hurdle is
still the reliable detection of rare preleukemic clones.
Recent functional studies on fusion gene products suggest that
those cells carrying fusion proteins might be more susceptible
to secondary events. MLL fusion proteins interfere with the
downregulation of HOX genes, leading to a differentiation block
and immortalizing a precursor cell as target for subsequent
genetic changes.20 Similarly, the TEL–AML1 fusion protein
increases the number of hematopoietic stem cells in the bone
marrow as a latent reservoir for the accumulation of further
genetic hits.21FWhat is the developmental step at which the
preleukemic clone is arrested to accumulate secondary muta-
tions? Answering this question may offer insight into ways to
prevent tumorigenic progression.
Epidemiological and pediatric observations on the role
of the immune system
The suggestion that the timing and pattern of infectious exposure
in early life may be a determinant of childhood leukemia was
mooted over 70 years ago.22,23 More recent, however, has been
the hypothesis that ALL could arise as a rare abnormal response
to a common infection; two distinct and related hypotheses
about how this might occur have been proposed by Kinlen
and Greaves. Kinlen suggested that ALL could arise as a
consequence of exposure to a specific infection, which is
particularly evident at times of unusual population movements
and mixing.24,25 Greaves hypothesized that a deficit of exposure
to infectious agents in infancy and subsequent ‘delayed’
infectious challenge may be causal in the development of
B-cell precursor ALL in the peak ages of 2–5 years.26 While the
Greaves hypothesis is supported by studies that have looked at
day-care attendance,27 less support is derived from examination
of primary care data revealing that cases who developed B-cell
precursor ALL between 2–5 years of age had significantly more
(not less) clinically diagnosed infectious illness episodes in
the first year of life compared with controls. This suggests
that immune dysregulation in children who develop ALL may be
detectable several years before diagnosis.28,29 However, find-
ings on the role of infections depend strongly on the infectious
proxies that have been employed (for example, social contact of
parents and child, socioeconomic status, maternally reported
infections versus medical records, day care attendance), and
suggest an important role for the immune system in the
pathogenesis of B-cell precursor ALL.FDoes the infection-
driven inflammation lead to tumor development and promotion?
In this respect, a potential protective effect of atopic disease as
observed in epidemiological studies30 needs further considera-
tions and might be a key in our understanding of the role of the
immune system in both diseases.
Are preleukemic clones affected by virus-induced (auto-)
immune reactions? Evidence for either direct or indirect
immune-mediated rejection of a preleukemic clone has
been observed in a healthy monozygotic twin of a child with
MLL-rearranged ALL. The child lost the preleukemic cell
population during transient, likely immune-mediated cyto-
penia.31FCan this be generalized and, if yes, by what
mechanisms are virus infections involved in the clearance of
the preleukemic clone? Or, alternatively, can infections trigger
secondary events or enhance their potency to drive preleukemic
cells toward leukemia? What are the conditions that trigger
enhanced (re)generation of B cells and their precursors?
Cellular plasticity and the role of the microenvironment
Although cellular differentiation processes had long been
considered unidirectional and irreversible, a set of experiments
in mice uncovered a high developmental plasticity of
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hematopoietic cells. The loss of a single transcription factor, Pax
5, allows mature B cells from peripheral lymphoid organs to
de-differentiate in vivo back to uncommitted progenitors in the
bone marrow. These de-differentiated progenitors were subse-
quently even able to develop into macrophages.32 The high
plasticity and lineage conversion imply that studying the disease
at the onset of clinical leukemia does not allow to retro-
spectively reveal the individual history, for example, the initial
first event. Thus, the nature of the cell-of-origin cannot
be identified by studying ALL samples at diagnosis.33 As a
consequence, prospective study designs and animal models are
needed.FWhich prospective study design can be performed?
The stromal microenvironment is known to be important in
B-lineage development and differentiation. Studies in mice
could demonstrate that alterations in the hematopoietic stem
cells niche (for example, mesenchymal cells) can lead to the
development of myeloproliferative disease and secondary
leukemia.34 Surprisingly, leukemia-specific genetic aberrations
were recently also found in mesenchymal stem cells (MSCs) of
some ALL cases, but the frequency of this finding varies
significantly and seems to be higher in relapse.35,36FWhat is
the role of the microenvironment in the persistence of
preleukemic clones? Are (some of) the genetic aberrations
caused by plasticity of leukemia cells? Is the correlation
between aberrations in MSCs and prognosis/relapse observed
in a limited number of patients also significant for a larger study
cohort? (If so, this could be useful as prognostic marker.) Can the
highly variable frequency of leukemia-specific translocations in
MSC be correlated with any known risk factor? Do other cells in
the affected individuals also carry these aberrations?
Animal models and innovative study designs
A ‘multi-hit’ model is highly desirable to study the mechanisms
of initiating events (genetic, epigenetic or environmental hits) as
well as the nature and role of the further hits, their kinetics and
age dependence (intrinsic versus extrinsic factors: chemicals,
radiation, infections/inflammation, immune control of malig-
nant progression), as this would allow hazard assessment studies
of potential risk factors.37
So far, the exposure of wild-type and some genetically altered
mice strains to magnetic fields that have been classified as
‘possibly carcinogenic’ (class 2b) by IARC did not confirm the
epidemiological findings of low-frequency fields as risk factors.
It cannot be excluded, however, that the negative results are at
least partially due to the use of inadequate, that is, insensitive,
animal models. Data from a new double-knockout mouse
model (loss of p19Arf and Rag1) were presented at the meeting38
and showed that p19Arf is a tumor suppressor in the Rag1-
deficient B-cell precursor cells, as the combined loss resulted in
B-cell precursor leukemia in mice. This raised the question
whether this and other animal models generated so far (for
example, MLL-AF9 model, see Stubbs et al.39; TEL-AML1 model,
see Ford et al.40; TEL-AML1 model, see Schindler et al.21) are
suitable and generally available or still have shortcomings that
need to be overcome. There was a strong feeling in the group
that, in addition to refinement of existing models, the generation
of new, more adequate animal models is also necessary, as
during the last years new insights on the hierarchical structure of
the disease and on genotype–phenotype correlations have been
gained.41 The risk that these new models might still not manage
to faithfully reproduce all aspects of human pathology is still
high, but their generation and analysis are considered to add
valuable information on mechanisms that cannot be gained
otherwise.
A solid mechanistic understanding of leukemia development
is also intended in animal studies and in vitro assays by
using retrovirus-based vectors for insertional mutagenesis.42,43
The retroviral vector insertion sites are frequently located in or
near proto-oncogenes or signaling genes and the resulting
insertional dominance database has led to the identification of
genes that stimulate or transform hematopoietic stem cells or
progenitor cells. Taken together, insertional mutagenesis
provides a relatively unbiased tool for screening approaches as
well as for functional studies on genes of interest complement-
ing other ongoing study designs.
Modeling
As the latency for childhood ALL is short, it has been suggested
that only a small number of rate-limiting steps are responsible
for overt leukemia. Little et al.44 could model most subtypes of
ALL by assuming only rate-limiting steps. Recent studies in mice
revealing an unanticipated high plasticity of lymphocytes32,45
and the newly uncovered role of the microenvironment35,36 will
lead to development of existing models, which have been
recently reviewed.46
In conclusion, the discussion on the above topics has led to the
identification of the most important research areas in the near
future and the following first-research agenda was developed.
Research recommendations
Human studies
(A) Investigations on the prevalence of ‘first-hit’
events. The focus should be on confirming the prevalence
of TEL-AML1, but also other less frequent chromosomal
translocations such as AML1-ETO, MLL-AF4, MLL-ENL,
MLL-AF9 and E2A-PBX should be considered.
(A1) Prevalence of the preleukemic clone: Samples from
existing Western Caucasian birth cohorts are preferable, as this
would offer the possibility of follow-up for disease and, thus,
would allow for the first time to develop and apply a prospective
study design. In addition, many data and possible risk factors
from the individuals of a birth cohort are available (parental
age, birth weight, atopic disease, and so on), including
some environmental exposure data. The anticipated number
of samples that would need to be screened is approximately
40 000. The sample size needs to be sufficiently large to address
the question whether the gender difference in ALL incidence
rates can be explained by a gender difference in the prevalence
of TEL-AML1.
(A2) Comparison of regional differences by focusing on
regions with maximally reported ALL incidence rate differences
(for example, regional differences reported to be up to threefold
between the Caucasian population and developing countries
in Central Africa). Data relating to the incidence of ALL in
developing countries are sparse and those existing are often of
poor quality. Therefore it is important to try and ascertain what
the disease incidence and the prevalence of TEL-AML are
in these countries.
Methodology and conditions to be developed:
 A network has to be established for defining a study protocol
and for developing an infrastructure for standardized testing
of ten thousands of samples (one place versus several places,
for example, set up a lab in Africa that could also be used for
other purposes).
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 Development of a set of validated PCR primers as a tool to
detect the presence of the most frequent translocations at
the genomic level.
 The availability of previously collected cord blood samples
(with low or known ethnic diversity) has to be established,
as well as possible overlap or synergism with ongoing or
planned studies.
 There are several ethical issues with a prospective design that
have to be considered. Informed consent of parents is needed.
One issue that needs to be carefully addressed is how to
deal with those children who have the TEL-AML1 or other
pre-disposing translocations.
(B) Deep sequencing. Characterization of the somatic
changes by whole-genome sequencing of ALL cases taken from
populations with different incidence rates (genome or exome,
transcriptome, epigenome).
(B1) Deep sequencing of ALL individuals in a stepwise
approach: A pilot study (n¼ 10, whole-genome or transcriptome
sequences, exome capture and sequencing) on individuals
already analyzed by GWASs would enable the comparison of
different methods. In a next step, whole-genome sequencing
of unselected ALL incident cases of one diagnostic year
(for example, in Germany) is recommended (including data
collection on possible risk factors like parental age, birth weight,
birth order, diet, and so on). In addition, deep sequencing of
predisposed children (from Project A1) is considered to add
valuable information. Finally, sequencing of ALL cases from a
population with low incidence rates in developing countries
(Central Africa) should reveal population differences.
Information on somatic and transcriptome changes will also
be a prerequisite for the development of predictive models that
could help in detecting environmental effects and allow
individually optimized treatment (http://www.treat1000.org).
(B2) Deep sequencing of the preleukemic clone from
predisposed children (from Project A1): Critical step: How can
the preleukemic clone be detected and isolated? As one single
cell might not be enough for ‘error-free’ whole-genome
sequencing, transcript analysis of the preleukemic clone could
be a starting point.
Methodology and conditions to be developed:
 The development of a standardized questionnaire is
necessary.
 In the prospective study design on predisposed individuals
(from Project A1), sample collection, for example, skin biopsy
or saliva samples, has to be validated.
 Again, ethical issues are considered to be difficult and need
clarification. Informed consent of parents is needed and
ascertainment of a ‘newly screened’ population versus
already collected biological material. How to convert a
program of genetic screening in, for example, an African
country into something beneficial for the population
as whole should be determined.
(C) Study the role of the hematopoietic stem cells niche
(for example, mesenchymal cells) for the origin and
maintenance of ALL. (C1) Verification of the correlation
between leukemia-specific aberrations in MSCs and prognosis/
relapse observed in a limited number of patients in a larger
cohort (for example, in the unselected ALL incident cases of one
diagnostic year from Project B1), including the correlation with
data collected on possible risk factors such as parental age, birth
weight, birth order, diet, and so on. It should be analyzed
whether other cells in the affected patients also carry these
aberrations (for example, endothelial cells, CD133 cells,
osteoblasts, myeloid cells).
In a next step, the results should be compared with
frequencies of leukemia-specific aberrations in MSCs in
populations with different incidence rates.
Methodology and conditions to be developed:
 Usage of the developed set of validated PCR primers of
Project A1 for detecting the most frequent translocations.
Animal models
The ultimate goal is to be able to mimic in the mouse the entire
molecular, cellular, tissular and organic features of human
B-ALL, including its initiation, progression, evolution, response
to therapy and eventual cure or relapse.
(D) Generation of appropriate mouse models.
(D1) Check availability of existing animal models and the need
for further refinement.
(D2) Generation of several new mouse strains (at the same
time): Among the different technical approaches available
(transgenesis, retroviral introduction of mice or human hema-
topoietic cells, or injection of human leukemic cells into mice),
germ-line transgenesis is preferred, as the generated mice strains
can be shared. Coupling with imaging techniques/markers
and/or gene marking or biotinylation is of help for further
analysis. A moderate susceptibility of the strain is desired, as this
allows the analysis of further hits. In all steps a comparison with
clinical data has to be established.
Subproject: Generate mouse strains to dissect the contribution
of non-hematopoietic cells to leukemia development (transloca-
tions under an MSC-specific promoter).
Analysis of host genetic background in leukemia develop-
ment: As shown in a mouse model by Wang et al.,47 the lineage
fate of leukemia cells (B-ALL versus AML) was determined by
the host microenvironment.
(D3) After having decided on a given model from
Projects D1 or D2
1. Exposure of animals to possible risk factors (radiation,
chemicals, infections/inflammation, replicative stress and so
on) followed by complete phenotyping with standardized
protocols.
2. Generation of a B-cell leukemia model of controlled genetic
variability with a backcross between two syngeneic mouse
strains (a resistant one and a susceptible one). It will permit to
study, using an integrative systems biology approach and
in a common scenario, the (multiple) low-susceptibility
genes that determine essential aspects of variability in B-ALL
behavior among individuals.
3. Exposure of a cohort of this B-cell leukemia model of
controlled genetic variability to possible risk factors.
These steps need biometric planning and consideration of the
3Rs (reduce, refine, replace).
Methodology and conditions to be developed:
 Standardization of mouse phenotyping (mouse hospital,
pathology, imaging techniques, molecular assays and so on).
 Development of methods for detection of clonal kinetics.
(E) Verification of the contribution of gene variants
identified in human studies to the development of B-cell
leukemias in mice
Causes of childhood leukemia
G Ziegelberger et al
4
Blood Cancer Journal
(F) Verification that the mechanisms outlined in A–E can
quantitatively account for the totality of human data,
via construction of novel quasi-mechanistic models
Concluding remarks
It was concluded that the exchange between different dis-
ciplines is a valuable and complementary approach to many
ongoing studies. Some essential questions can be addressed
only by combined efforts in an interdisciplinary network.
The research agenda will be used by BfS for fund raising at
the national and European level.
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